Compare Inovio Pharmaceuticals Inc (INO) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Northrop Grumman Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Northrop Grumman Corporation trades at $480.72 (market cap $68.83B). The key difference: Northrop Grumman Corporation is far larger — about 613.5× Inovio Pharmaceuticals Inc's market cap, and Northrop Grumman Corporation pays a 2.04% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Northrop Grumman Corporation for 81 Days on average.
| INO | NOC | |
|---|---|---|
Market Cap | $112.19M | $68.83B |
Volume | 3,201,278 | 1,081,989 |
Sector | Health | Industrials |
52-Week High | $2.60 | $768.02 |
52-Week Low | $0.66 | $473.46 |
Typical Hold Time | 43 Days | 81 Days |
Enterprise Value | $83.51M | $82.81B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
Northrop Grumman (NOC) trades at $484.48, up 2.33% on the day, but technical indicators signal a bearish trend. The company demonstrates strong fundamentals with consistent earnings beats, a net income margin of 10.48%, and a robust backlog. Recent news highlights a competitive setback with Boeing winning a major Navy contract, though the company maintains solid defense sector positioning.
The outlook is mixed; strong profitability and analyst buy ratings support upside to a $600.62 consensus target, but near-term technical pressure and contract loss risks pose challenges. Revenue growth and dividend stability offer investor appeal, though sector volatility and execution risks require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
